Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The drug that is under investigation during this study is RhuDex® and is expected to be used as an oral treatment for rheumatoid arthritis. Normal stomach juices contain acid and previous studies have shown that this acidity reduces the solubility and therefore the absorption of RhuDex®. Administering the alkaline buffer meglumine with RhuDex® has shown to increase the solubility of RhuDex® by decreasing the stomach acidity.

The purposes of this study are to determine:

* the optimum level of meglumine which is required to achieve the best uptake of RhuDex® from the stomach into the blood
* to determine the concentration of RhuDex® in the blood in the presence of the optimum level of meglumine
* to investigate further the safety and tolerability of RhuDex®. The study will be conducted in healthy male volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RhuDex® is a novel, orally bioavailable, low molecular weight modulator of co-stimulation of T lymphocytes. RhuDex® binds to the protein CD80 on the surface of antigen-presenting cells and inhibits its interaction with CD28 (but not with CTLA-4) presented by CD4+ T lymphocytes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pharmacokinetics

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Rheumatoid Arthritis RhuDex® Meglumine Oral Bioavailability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RhuDex®

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male subjects between 18 and 60 years at the time of enrollment
* Male volunteers and their partners who are of child-bearing potential must agree to use a double-barrier method of contraception during the study and for 12 weeks after discharge
* BMI between 18.5 and 29.9 kg/m²
* Written informed consent
* Ability to comply with the requirements of the study

Exclusion Criteria

* Acute infection at time of enrollment
* History of chronic inflammation, chronic infection, other chronic disease, autoimmune disorders (e.g. diabetes mellitus) or cancer
* Clinical significant abnormal ECG
* Clinical significant abnormal laboratory values (especially in terms of liver or renal insufficiency)
* Clinically significant physical findings
* Major surgery within the last 4 weeks prior to enrollment
* Organ allograft recipient
* Concomitant or planned treatment which would interfere with study results
* Any systemic medical treatment, including over the counter products and dietary supplements such as iodine, fluoride or vitamins, within one week before and during the study course
* Known allergy against any ingredient of the study medication or meglumine
* Participation in an investigational trial within 30 days prior to enrollment
* Systemic intake of immunosuppressive or immunomodulatory medication or vaccination within 30 days prior to enrollment and for the whole study duration
* Blood loss exceeding 450 mL (including blood donations) within 12 weeks prior to enrollment into the study
* Medical history of alcohol or drug abuse or alcohol consumption greater than 21 units per week for males. A unit of alcohol is equivalent to: half a pint of average strength beer (280 mL), a glass (125 mL) of wine or a standard measure (25 mL) of spirits, sherry or port
* A positive alcohol breath test
* A positive urine drug screen
* Regular smokers (more than 20 cigarettes or 5 cigars per day)
* Presence of hepatitis B surface antigen (HBsAG), hepatitis C antibody (HCV Ab) or HIV-1 or HIV-2 antibodies at screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MediGene

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen Freestone, MD

Role: PRINCIPAL_INVESTIGATOR

Syneos Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charles River Clinical Services Edinburgh Ltd

Edinburgh, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CT 5001

Identifier Type: -

Identifier Source: org_study_id